Analyst consensus rating
Monte Rosa Therapeutics Analyst Rating: Strong Buy
Direct answer
Monte Rosa Therapeutics's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.38.
Forecast evidence checked November 16, 2026.
Get free Monte Rosa Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.37
- Average price target
- $25.38
- High price target
- $37.00
- Low price target
- $15.00
- Low target gap
- +60.1%
- Target upside
- +170.8%
- High target gap
- +294.9%
- Target range width
- 234.8%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- November 16, 2026
- Valid through
- November 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Monte Rosa Therapeutics?
Monte Rosa Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $25.38.
How far are Monte Rosa Therapeutics's low and high targets from the recorded price?
The low target implies +60.1%, while the high target implies +294.9%.
How many analysts are included in Monte Rosa Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is Monte Rosa Therapeutics's target upside or downside calculated?
The average target of $25.38 is divided by the recorded price of $9.37, then one is subtracted to produce +170.8%. This does not guarantee a future return.
When was Monte Rosa Therapeutics's analyst forecast verified?
The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.